Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's …

KA Johnson, S Minoshima, NI Bohnen… - Alzheimer's & …, 2013 - Elsevier
Positron emission tomography (PET) of brain amyloid β is a technology that is becoming
more available, but its clinical utility in medical practice requires careful definition. To …

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education

KA Johnson, S Minoshima, NI Bohnen… - Alzheimer's & …, 2013 - Wiley Online Library
Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the
two defining pathologic lesions of Alzheimer disease, amyloid‐β deposition in the brain. The …

Amyloid PET imaging in clinical practice

MA Kolanko, Z Win, F Loreto, N Patel, C Carswell… - Practical …, 2020 - pn.bmj.com
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …

[HTML][HTML] Amyloid PET imaging: applications beyond Alzheimer's disease

AM Catafau, S Bullich - Clinical and translational imaging, 2015 - Springer
As a biomarker of beta-amyloid, positron emission tomography (PET) amyloid imaging offers
a unique opportunity to detect the presence of this protein in the human body during life …

Clinical use and utility of amyloid imaging

H Barthel, O Sabri - Journal of Nuclear Medicine, 2017 - Soc Nuclear Med
Currently, 3 amyloid PET tracers are approved and commercially available for clinical use.
They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer …

Clinical amyloid imaging

A Mallik, A Drzezga, S Minoshima - Seminars in nuclear medicine, 2017 - Elsevier
Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of
Alzheimer disease (AD). Recently, amyloid PET radiotracers have been developed and …

The role of amyloid PET in imaging neurodegenerative disorders: a review

M Chapleau, L Iaccarino… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Imaging of amyloid deposition using PET has been available in research studies for 2
decades and has been approved for clinical use by the US Food and Drug Administration …

[HTML][HTML] A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of …

ER Fantoni, A Chalkidou, JT O'Brien… - Journal of …, 2018 - content.iospress.com
Background: Amyloid PET (aPET) imaging could improve patient outcomes in clinical
practice, but the extent of impact needs quantification. Objective: To provide an aggregated …

[HTML][HTML] The who, when, why, and how of PET amyloid imaging in management of Alzheimer's disease—Review of literature and interesting images

S Suppiah, MA Didier, S Vinjamuri - Diagnostics, 2019 - mdpi.com
Amyloid imaging using positron emission tomography (PET) has an emerging role in the
management of Alzheimer's disease (AD). The basis of this imaging is grounded on the fact …

Brain amyloid imaging

CC Rowe, VL Villemagne - Journal of nuclear medicine …, 2013 - Soc Nuclear Med
Imaging of brain β-amyloid plaques with 18F-labeled tracers for PET will likely be available
in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly …